D-Stat Radial is a dry version of the D-Stat together with a compression band, and is designed for the control of surface bleeding from vascular access sites, including the sites on the radial artery
The EVS is engineered to close arteriotomies with ease and precision. The ergonomic stapler with a simple trigger actvated mechanism, requires a single operator. A deliver sheath gently locks onto
...d of an absorbable collagen sponge and a specially...n absorbable self-tightening suture. The device se... primary components, the anchor and the collagen s...echanical means and is supplemented by the platele...
Spyglass angiography catheters, combined with St. Jude Medical hemostasis introducers and GuideRight guidewires, offer a safe and effective diagnostic angiography system.
Medicine Products:(Date:12/3/2008)...ic study found that patients with low-grade glioma...surgeries to successfully remove the entire tumor....ble, patients survived significantly longer when s...dy is available online as an advance publication i...rnals.org/cgi/content/abstract/15228517-2008-102v1...
(Date:12/3/2008)...ater Than Entire U.S. Economy , , DALLAS, D...vernment stopped the Medicare and Social Security ...xes and allowing no more accrual of benefits -- it...ave already earned these benefits, according to a ...is (NCPA). , , "The numbers are staggerin...
(Date:12/3/2008)...swire-FirstCall/ -- MAP,Pharmaceuticals, Inc. (Na...ill,participate in a panel discussion titled "Ada...ons" at the 2008 RBC Capital Markets Healthcare Co...0 am (ET) in New York City. , A live webcas... Investor,Relations section of MAP Pharmaceutical...
(Date:12/3/2008)...he Baccalaureate Student Population May Signal tha... , WASHINGTON, Dec. 3 /PRNewswire-USNewswire/ -...(AACN) today released preliminary survey data show...ursing programs increased by only 2.0 percent from...cutive year of enrollment growth, the annual incre...
Breaking Medicine News(10 mins):Health News:Mayo Clinic identifies best treatments for long-term survival in brain tumor patients 2Health News:Medicare, Social Security Owe Up to $52 Trillion to Current Retirees and Workers 2Health News:Enrollment Growth in U.S. Nursing Colleges and Universities Hits an 8-Year Low According to New Data Released by AACN 2Health News:Enrollment Growth in U.S. Nursing Colleges and Universities Hits an 8-Year Low According to New Data Released by AACN 3Health News:Enrollment Growth in U.S. Nursing Colleges and Universities Hits an 8-Year Low According to New Data Released by AACN 4Health News:Enrollment Growth in U.S. Nursing Colleges and Universities Hits an 8-Year Low According to New Data Released by AACN 5(Date:12/2/2008)...reyPines Therapeutics, Inc. (Nasdaq: TPTX ) toda...se II trial evaluating three doses of NGX267 as a ...s with Sjogren,s syndrome. NGX267 met the primary...in salivary flow production compared to placebo at...oses were safe and well tolerated with few reports...
(Date:12/1/2008).../ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA ) ...rld,s leading medical journals, results of clinica...ental compound tasimelteon (VEC-162). The publica... agonist tasimelteon (VEC-162) for transient insom...led multicentre trials." Results are reported from...
(Date:12/1/2008)...-way switch that, if turned off, causes lymphatic ...lose their identity and become more like blood end...PRNewswire-USNewswire/ -- Scientists at St. Jude ...a certain differentiated cell type is so ready to ...expression of a gene called Prox1 to dissuade it...
(Date:12/1/2008)...oVax Labs, Inc.,(OTC Bulletin Board: GOVX), an At...n vaccines for diseases caused by HIV-1 (Human Imm... announced today that the launch of its Phase 2a H...es across North and South America.,These trials a...stitutes of,Health (NIH), and the HIV Vaccine Tri...
Breaking Medicine Technology:TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 2TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 3TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 4TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 5Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3Moderate Aerobics May Ease Insomnia Symptoms 21763 1Trust for Americas Health Releases Report on Connection between Womens Health and Stalled Infant Mortality Rates 21759 1Trust for Americas Health Releases Report on Connection between Womens Health and Stalled Infant Mortality Rates 21759 2Trust for Americas Health Releases Report on Connection between Womens Health and Stalled Infant Mortality Rates 21759 3Speaker Training 3A Driving Program Impact 26 Influence 21755 1Dental Services Expand to Serve More Than 280 000 Michigan Children 21751 1Dental Services Expand to Serve More Than 280 000 Michigan Children 21751 2...e for Second Pivotal Phase 3 Trial CL-05, CHICAGO,...Life,Sciences Holdings, Inc. , today announced the...rial CL-06, the first of two,pivotal Phase 3 clini...tiveness of cethromycin, a novel once-a-day antibi...monia (CAP). The Company,also provided an update t...
...007 -- Ablynx today announced positive,interim res...velopment programme, ALX-0081, an anti-thrombotic ...ss´ therapeutic,Nanobody® targeting von ... of thrombosis in patients with acute coronary,syn...s designed to assess,safety, tolerability and phar...
Other Medicine Technology:Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 2Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 3Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 4Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 5Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 6Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 7Ablynx Announces Interim Results of First Nanobody Phase I Study of,ALX-0081 (ANTI-VWF) 2